The High-Risk Prescription of Hope

The University of California, San Diego study on leucovorin prescriptions for children with autism reveals a disturbing trend: after President Trump and other officials touted its potential benefits, the prescription rate skyrocketed by 2,000%. This surge was fueled by media attention and public statements from White House officials.

Researchers emphasize that their study does not weigh in on leucovorin’s effectiveness for autism. However, they acknowledge that widespread promotion of this medication has put many families at risk. Leucovorin may have benefits for children with cerebral folate deficiency, but there is no convincing evidence to support its use as an autism treatment.

The Trump administration’s endorsement of leucovorin was always tenuous. A debunked claim linking acetaminophen (Tylenol) to an increased risk of autism in children had been quickly discredited by experts. Yet White House officials persisted in promoting leucovorin as a potential breakthrough treatment, despite the lack of supporting evidence.

The consequences of this misinformation are far-reaching. Many families have been convinced that leucovorin holds the key to improving their children’s symptoms, particularly speech deficits. However, data suggests these claims were based on weak and incomplete research. The largest trial of the drug was recently retracted due to errors in the data.

The FDA’s decision not to endorse leucovorin as an autism treatment is a welcome development. However, more needs to be done to protect families from unsubstantiated claims and misinformation. As researchers note, generating rigorous data on long-term outcomes for children who have taken leucovorin for autism is essential.

The story of leucovorin raises important questions about the responsibility of public officials to provide accurate information to families in need. The promotion of unproven treatments can have devastating consequences, particularly when it comes to vulnerable populations like those with autism and their families. Policymakers must prioritize evidence-based decision-making over sensational claims and media attention.

The Media’s Role in the Leucovorin Fiasco

Fox News reported on several families who believed leucovorin had improved their children’s symptoms, particularly speech deficits, in February 2025. This reporting helped fuel the subsequent spike in leucovorin prescriptions. However, not all media outlets were equally enthusiastic. The New York Times, for example, noted in September 2025 that “while some small studies have shown promise, we don’t yet have convincing evidence to recommend this treatment to all children with ASD.”

The media’s role in promoting or debunking unproven treatments is complex. Sensational reporting can draw attention to important issues and spark public debate, but it also risks perpetuating misinformation and harming vulnerable populations.

The Long-Term Consequences of Leucovorin Prescriptions

Rigorous data on the long-term outcomes for children who have taken leucovorin for autism is crucial in determining whether this medication has any actual benefits. However, it’s also worth considering the potential consequences of widespread use: what if further research shows that leucovorin has no benefits for autism but rather exacerbates existing conditions or creates new ones?

The Broader Implications of Misinformation in Medicine

The story of leucovorin highlights the dangers of misinformation in medicine. It emphasizes the need for policymakers and public officials to prioritize evidence-based decision-making over sensational claims and media attention. However, this issue is not unique to the medical field; misinformation and disinformation are increasingly prevalent in many areas of public policy, from climate change to education reform.